CALLAN JMB INC.

Callan JMB Inc. has received a determination from Nasdaq that it has failed to meet the minimum stockholders' equity requirement for continued listing. The company was previously notified of a deficiency and granted an extension until October 5, 2026. As capital raising initiatives were unsuccessful, Nasdaq has determined non-compliance. Trading suspension and delisting are set for October 21, 2026, unless an appeal is filed by October 19, 2026. The company has requested a hearing to appeal this determination and intends to demonstrate compliance.

Callan JMB Inc. announced the successful completion of emergency preparedness support for the City of Chicago during the 2026 Lollapalooza weekend. This engagement continues the company's long-standing work supporting the city during major public events and periods requiring heightened preparedness, a partnership that began in 2009 with the H1N1 response. The company provided extensive logistical and operational capabilities for the event, which drew approximately 460,000 attendees, alongside other major city events. Both the COO and CEO expressed pride in their team's efforts and the continued trust placed in Callan JMB to support these critical operations.

Callan JMB Inc. announced breaking ground on the Marion 9 Biomanufacturing Center at its Atlas Complex, marking a strategic partnership with Alabama State University. This venture aims to strengthen U.S. domestic pharmaceutical production and supply chain resilience. The project is forecast to generate $500 million in annual gross revenues for the partnership, with Callan JMB receiving a 21% share, equating to approximately $105 million in the first year and over $400 million over five years. The initiative is also expected to create over 150 direct and 300 indirect jobs in Alabama.

Callan JMB Inc. announced a strategic partnership with Alabama State University (ASU) to develop an integrated pharmaceutical manufacturing ecosystem. This collaboration aims to strengthen domestic pharmaceutical production, enhance supply chain resilience, and advance workforce development. Callan JMB will provide operational infrastructure and expects to receive 21% of gross revenues from the initiative, which management believes could generate $414 million in five-year revenue and potentially $105 million in annual revenue for the company.

Callan JMB Inc. has formed a strategic partnership with Alabama State University to advance workforce development, applied research, and industry collaboration at its Atlas Complex. This collaboration aims to accelerate domestic pharmaceutical manufacturing and strengthen U.S. healthcare supply chains by integrating higher education, industry, and workforce development. The Atlas Complex, a 150-acre pharmaceutical and medical logistics campus, is projected to generate over $430 million in annual revenue at maturity.

Callan JMB Inc. received a notice from Nasdaq on June 29, 2026, indicating non-compliance with the minimum $1.00 bid price requirement for continued listing. The company's common stock traded below $1.00 for 30 consecutive business days. Callan JMB has an initial 180-calendar-day period, until December 28, 2026, to regain compliance by maintaining a closing bid price of at least $1.00 for a minimum of ten consecutive business days. The company is considering options, including a reverse stock split, to address the deficiency.

Eric Kash resigned from his positions as Executive Vice President and a member of the Board of Directors of Callan JMB Inc., effective June 5, 2026. His departure was not due to any disagreement with the company. In connection with his resignation, Mr. Kash and the company entered into a Settlement, Waiver and Release Agreement, which includes a severance payment of $125,000 and the retention of his 187,500 vested stock options.

Callan JMB Inc. announced it has received a Vaccines for Children (VFC) Program PIN authorization from the State of Oregon. This approval significantly expands the company's capabilities to support public health programs by enabling the storage, management, preparation, and distribution of pediatric vaccines and other temperature-sensitive medical materials. The authorization strengthens Callan JMB's ability to provide efficient logistical support for both routine public health operations and targeted response efforts, aligning with its strategy to expand its healthcare logistics platform.

Callan JMB Inc. has entered into an At-The-Market Issuance Sales Agreement with Alexander Capital, L.P., enabling the company to sell up to $5,000,000 of its common stock. Sales will occur "at the market" on the Nasdaq Capital Market or other trading venues. The company intends to use the net proceeds from this offering for working capital and general corporate purposes.

CALLAN JMB Inc. reported a significant widening of its net loss to $(3.22) million for Q1 2026, a 159% increase from the prior year, while revenue decreased by 23.7% to $1.11 million. The company also disclosed a going concern warning due to accumulated deficits and continued net losses. To address liquidity, CALLAN JMB has utilized its Equity Line of Credit (ELOC) facility, raising $1.55 million with $23.45 million remaining available, and extended its maturity to April 2027.